Team

  • Leaders: K Clément (PU-PH) and J Aron-Wisnewsky (MCU-PH)
  • Team Contributors: R Alili, C Poitou, S André, I Dugail, M Guerre-Millo, N Sokolovska, H Soula
  • Main collaborators: JD Zucker, International consortia Metacardis, ePos, Litmus (IMI2), INRA

Main Objectives

  1. Define gut microbiota signature in CMD and evaluate the impact of environment (diet and drugs)
  2. Demonstrate causality of CMD microbial signature in the development of CMD or its resolution:
    • in human interventions: Metacardis follow-up (development), diet or bariatric surgery (reversal)
    • in mice: gut microbiota transfer experiments (induce CMD or its reversal)

Results

Topic 1 : Progression of obesity and related complications: role of gut microbiota?
Progression of obesity and related complications: role of gut microbiota?
TOPIC 1
Intestine as a key player in metabolic disorders
TOPIC 2
Adipose tissue Remodeling
TOPIC 3
Systems’ biology and data integration (transversal WP)
TOPIC 4
Translating our fundamental research for the benefit of patients
TOPIC 5